Menu
CEO360 provides a network around CEOs
Peer group of 20-25 fellow CEOs
CEO supported by specialized trusted advisors
CEO Introduced to VC and PE investors
When CEOs face tough decisions, their fellow peers become their informal Advisory Board — a continuation of the efforts that happen in a CEO360 Group Meeting, becoming the First Ring of Support.
Having a network of Trusted Advisors is an invaluable asset to a CEO trying to move their company forward. With access to the top Life Sciences Trusted Advisors connected to CEO360, a CEO has the peace of mind that they are making solid decisions about critical matters.
CEO360 hosts quarterly Pitch Contests including Venture, Corporate Venture, Family Office, and Private Equity investors. As a member of the CEO360 program, CEOs will develop relationships, receive feedback, and coaching from active Life Science investors. The Third Ring of Support.
David H. Crean, Ph.D.
Managing Partner
Cardiff Advisory
David has 30+ years of buy and sell-side expertise of M&A, partnering and investments within the life sciences and healthcare sectors working within strategic biopharmaceutical companies, private equity, investment banking and venture capital.
He serves as Managing Partner for Cardiff Advisory LLC, a boutique mergers & acquisitions FINRA investment banking and strategic advisory firm focused on M&A and partnering collaborations for life sciences and healthcare companies. He currently serves as an advisor to more than 40 entrepreneurs and their companies.
In parallel to his investment banking activities, David is an emerging fund manager and raising capital from limited partners for Coast BioVentures, a $50 million life sciences fund focused on the Southern California market.
David currently serves in leading Boards of Director roles for Histogen, Inc. (Nasdaq: HSTO), Paracrine Inc., Almon Therapeutics, California Life Sciences (CLS), and BIOCOM California as Chair of Capital Development. He is also Chairman Emeritus of the Board for the Alzheimer’s Association for San Diego/ Imperial Counties.
LinkedIn Profile
Tari Suprapto, Ph.D, RTTP
Director, Search & Evaluation (West)
Novo Nordisk
Tari Suprapto, Ph.D., RTTP is a seasoned technology commercialization professional in the life sciences. She is currently the Director for Search & Evaluation for Western US and Canada for Novo Nordisk, and previously was part of the External Innovation team at Elanco.
Tari spent over 15 years commercializing innovations from world-class research institutions such as the Salk Institute, The Rockefeller University, and Memorial Sloan-Kettering Cancer Center.
Tari has extensive experience in licensing, building and managing strategic alliances, and a strong scientific background in a variety of therapeutic areas evidenced by her Ph.D. in cell biology from The Rockefeller University and an Honors B.A. from Swarthmore College.
Tari is also a member of BIOCOM’s Capital Development Committee and serves on the boards of the Association for University Technology Managers, the San Diego Innovation Council, and official advisor to Founders Corner Venture Capital in San Diego.
John Foley
Chief Revenue Officer
Arrow Up Staging
John currently serves privately-held middle market companies by preparing them for an investment transaction or exit, making them "Exit Ready". John also co-chairs Life Science, Biotech and MedTech CEO peer-to-peer advisory groups advising CEOs in multiple stages including Startup, Early Venture, and Late Growth.
With over 30 years of business innovation and growth, John helps privately-held, middle market companies navigate the changing technology, marketing, sales, and digital landscape.
He helps businesses reimagine, reshape, and retool for an era in which traditional business models are being transformed.
With extensive experience with investor backed companies, John understands how to fast-track revenue growth, transform sales organizations, reposition and rebrand based on customer data and insights. John is a creative problem solver who anticipates the needs of the market and investors, and helps guide business stakeholders accordingly. Adept at building and managing relationships throughout the organization, and has a successful track record of leading cross-functional teams.
CEOs in a CEO360 environment find connections with excellent CEO’s, useful suggestions on how to improve their business. Trusted Advisors expose CEOs to real life strategies in nine key areas:
Fundraising
Emerging Growth
Transferable Economics
Compelling Solutions
Attractive Markets
GMP Manufacturing / Clinical Viability
Competitive Greatness
IP – Legal
Championship Team
CEO360 allows CEOs to find other CEOs facing similar challenges, learn and collaborate together. CEOs form meaningful friendships and become advisors to one another.
CEOs learn to trust each other, become open and vulnerable. The trust creates lively, candid discussions. There is nothing like seeing positive results to bolster a CEO’s level of confidence. In the CEO360 Program, CEOs are getting funded, winning grants, finding partnerships, and getting the advice they need at the exact right time.
CEO360 groups result in referrals and access to wide networks of support across the Life Science and M&A ecosystem. CEOs have doors opened to a wide variety of professionals, investors, and organizations just by belonging to a CEO360 Group.
The journey from Startup Stage to Early Venture Stage to Late Growth Stage is incredibly difficult.
Today, only 10% make it across the finish line. That’s frankly, unacceptable.
That is why we started CEO360 and structured it differently than other peer-to-peer advisory groups.
We understand that Life Science CEOs are different.
They are results driven.
They are smart but need help.
They feel a sense of urgency.
They believe their solutions are a matter of life and death will save the world (and they probably will).
To get funded vs. developing funding strategies.
Achieve big results vs. receive helpful coaching.
Build a valuable company vs. building a positive working environment.
Get through clinical trials vs. getting positive indications.
Securing intellectual property vs. thinking up great ideas.
Growing vs. planning for growth.
Winning a pitch contest vs. getting ready for a pitch contest.
Receiving funding vs. applying for a grant.
Being successful vs. learning about a recipe for success.
Using funds to create life-saving solutions vs. creating forecasts.
Honest feedback from a responsible fiduciary vs. sugar coating.
Commercial viability vs. hopeful indications.
Hiring a dream team vs. proposing a dream team.
Getting it done vs. learning about how to do it.
Acquiring their competition vs. thinking big.
Taking market share vs. crafting a go-to-market plan.
The Life Sciences Ecosystem is like no other. A complex web of high stakes challenges, life-saving implications for mankind, regulatory hurdles, and an impossible funding environment. All of these forces have been difficult on the Life Sciences CEO.
CEO360 has tapped the resources of trusted advisors, investors and the leading organizations in the Life Sciences community to come together and create a structure to move the Startup, Early Venture Stage and Late Growth Stage Life Science CEO front and center with opportunity. Not only is it a good thing to do, it’s the right thing to do. We believe the benefits will be exponential for the entire ecosystem.
© All Rights Reserved • Arrow Up Partners, LLC • 2023